B. Riley Securities Reiterates Buy Rating on ClearPoint Neuro

On June 18, 2026, B. Riley Securities reiterated its buy rating on ClearPoint Neuro, Inc. (NasdaqCM: CLPT), setting a price target of $30. The medical device company's stock was trading at $16.81 at the time of the announcement.

Other Institutional Activity in ClearPoint Neuro

Institutional investors have shown varying levels of interest in ClearPoint Neuro. BlackRock, Inc. increased its holdings by 39,117 shares, bringing its total to 2,082,750 shares valued at approximately $18.95 million. MAK Capital One LLC initiated a position with 1,901,489 shares, valued at $17.3 million. Vanguard Capital Management LLC also started a new position, adding 1,243,615 shares worth around $11.32 million. Geode Capital Management, LLC grew its stake by 51,375 shares to a total of 705,720 shares, valued at $6.42 million. Meanwhile, State Street Corp added 51,758 shares, ending with 679,819 shares worth about $6.19 million.

ClearPoint Neuro Stock Snapshot

Shares of ClearPoint Neuro, Inc. are trading at $16.81, with a market capitalization of approximately $532.9 million. The company's forward P/E ratio is not meaningful as it isn't currently profitable, with a negative EPS of -$1.00. ClearPoint Neuro's beta is 1.311, indicating a higher volatility compared to the market. The stock's 52-week range is between $8.27 and $30.10. It has a 50-day moving average of $12.02 and a 200-day moving average of $14.36. The company's current ratio is strong at 5.789, though it has a high debt-to-equity ratio of 337.498.

Recent Earnings

ClearPoint Neuro reported revenue of $40.61 million, showing a growth rate of 42.9%. However, the company is not currently profitable, with a net margin of -71.57% and a return on equity of -149.72%. The next earnings report is expected on August 11, 2026.

Insider Buying and Selling at ClearPoint Neuro, Inc.

There have been several insider transactions recently. Timothy Richards sold 500 shares at $10.00 each and bought 500 shares at the same price on June 4, 2026. He also sold 376 shares at $13.30 and 5,415 shares at $12.17 earlier in the month. Linda Liau and John Fletcher both purchased 12,820 shares on May 21, 2026.

Analysts Set New Price Targets

On June 18, 2026, B. Riley Securities maintained its buy rating on ClearPoint Neuro, setting a price target of $30. The consensus among analysts is a strong buy, with a mean target price of $22.00 based on three opinions.

About ClearPoint Neuro

ClearPoint Neuro, Inc., headquartered in Solana Beach, California, is a commercial-stage medical device company in the healthcare sector. It specializes in developing platforms for minimally invasive brain surgeries in the U.S. Its products include the ClearPoint systems, which provide hardware, disposables, and software for surgical planning and monitoring. The company also offers consulting services to partners in the medical technology field.

Bottom Line

B. Riley Securities' reiteration of its buy rating with a $30 target reflects confidence in ClearPoint Neuro's potential. Investors should note this is a backward-looking analysis based on historical data, and actual performance may vary. Institutional interest suggests some optimism about the company's future prospects.